We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CSL:NYSECarlisle Companies Incorporated Analysis

Data as of 2026-03-27 - not real-time

$333.64

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Carlisle Companies (CSL) is trading around $333.64, just above its 20‑day SMA of $353.42 and below the 50‑day SMA of $369.66, indicating a short‑term pull‑back within a neutral trend. The RSI of 34.9 points to oversold conditions, while the MACD remains bearish with the line below its signal, suggesting limited upside momentum in the near term. The stock’s beta of 0.88 and 30‑day volatility of 28.9% reflect moderate market sensitivity, and the current PE of 19.5 is well below the industry average of 28.5, supporting a value case despite a DCF‑derived fair value of roughly $204.
Recent accolades—first‑place rankings in Extel’s 2025 All‑America Executive Team and a resilient 2025 annual report—underscore operational strength, while a forward PE of 14.2 and a dividend yield of 1.29% with a modest 24.5% payout ratio highlight attractive earnings upside and dividend sustainability. However, a high debt‑to‑equity ratio of 168% and a sizable max drawdown of 32% flag balance‑sheet and downside risk, making the stock a nuanced play between growth potential and valuation caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price is near the identified support level of $324
  • RSI indicates oversold conditions that could prompt a bounce
  • Bearish MACD histogram suggests limited upside momentum

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward earnings estimate lifts the forward PE to 14.2, well below peers
  • Cyclical construction recovery expected to boost revenue growth
  • Strong cash generation and a sustainable dividend support total return

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • High ROE of 34.9% signals durable profitability
  • Elevated debt‑to‑equity ratio and a DCF fair value far below market price
  • Consistent dividend and strategic positioning in building‑products markets

Key Metrics & Analysis

Financial Health

Revenue Growth0.40%
Profit Margin14.75%
P/E Ratio19.5
ROE34.87%
ROA10.38%
Debt/Equity168.32
P/B Ratio7.6
Op. Cash Flow$1.1B
Free Cash Flow$749.6M
Industry P/E28.5

Technical Analysis

TrendNeutral
RSI34.9
Support$324.47
Resistance$396.24
MA 20$353.42
MA 50$369.66
MA 200$357.43
MACDBearish
VolumeStable
Fear & Greed Index71.93

Valuation

Fair Value$204.49
Target Price$396.63
Upside/Downside18.88%
GradeOvervalued
TypeBlend
Dividend Yield1.29%

Risk Assessment

Beta0.88
Volatility28.89%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.